H1N1 Infection - Pipeline Review, H1 2016

  • ID: 3720452
  • Report
  • 203 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Akshaya Bio Inc.
  • Cilian AG
  • Gemmus Pharma Inc.
  • Medicago Inc.
  • NanoViricides, Inc.
  • Sirnaomics, Inc.
  • MORE
H1N1 Infection - Pipeline Review, H1 2016

Summary

‘H1N1 Infection - Pipeline Review, H1 2016’, provides an overview of the H1N1 Infection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for H1N1 Infection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for H1N1 Infection and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of H1N1 Infection
- The report reviews pipeline therapeutics for H1N1 Infection by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved H1N1 Infection therapeutics and enlists all their major and minor projects
- The report assesses H1N1 Infection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for H1N1 Infection

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for H1N1 Infection
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding H1N1 Infection pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Akshaya Bio Inc.
  • Cilian AG
  • Gemmus Pharma Inc.
  • Medicago Inc.
  • NanoViricides, Inc.
  • Sirnaomics, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

H1N1 Infection Overview

Therapeutics Development

Pipeline Products for H1N1 Infection – Overview

Pipeline Products for H1N1 Infection – Comparative Analysis

H1N1 Infection – Therapeutics under Development by Companies

H1N1 Infection – Therapeutics under Investigation by Universities/Institutes

H1N1 Infection – Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

H1N1 Infection – Products under Development by Companies

H1N1 Infection – Products under Investigation by Universities/Institutes

H1N1 Infection – Companies Involved in Therapeutics Development

Adamas Pharmaceuticals, Inc.

Akshaya Bio Inc.

Altimmune, Inc.

Antigen Express, Inc.

Beijing Minhai Biotechnology Co., Ltd

CEL-SCI Corporation

Cilian AG

CSL Limited

EpiVax, Inc.

Etubics Corporation

Gemmus Pharma Inc.

iBio, Inc.

ILiAD Biotechnologies, LLC

Inovio Pharmaceuticals, Inc.

Johnson & Johnson

Kineta, Inc.

Kyowa Hakko Kirin Co., Ltd.

Medicago Inc.

MedImmune, LLC

Microbiotix, Inc.

Mucosis B.V.

NanoViricides, Inc.

NewLink Genetics Corporation

Novavax, Inc.

OPKO Health, Inc.

PeptiDream Inc.

Sarepta Therapeutics, Inc.

Sirnaomics, Inc.

Takeda Pharmaceutical Company Limited

TechnoVax, Inc.

Theraclone Sciences, Inc.

Touchlight Genetics Limited

United Therapeutics Corporation

Vaxart, Inc.

Vironova AB

Visterra, Inc.

Zydus Cadila Healthcare Limited

H1N1 Infection – Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

A-06 - Drug Profile

ADS-324 - Drug Profile

AEA-35p - Drug Profile

Antisense RNAi Oligonucleotides to Inhibit Matriptase for Influenza - Drug Profile

Aspidasept - Drug Profile

C-05 - Drug Profile

CiFlu - Drug Profile

CR-9114 - Drug Profile

diridavumab - Drug Profile

Fludase - Drug Profile

FluGEM - Drug Profile

FVH-1 - Drug Profile

Gamma-Flu - Drug Profile

GP-1001 - Drug Profile

GP-1681 - Drug Profile

GREFLU/CAL - Drug Profile

H1N1 [A/Aichi/2/68] vaccine - Drug Profile

HB-36.6 - Drug Profile

Human Antibody Based Vaccines - Drug Profile

iHA-24 - Drug Profile

infectious vaccine - Drug Profile

Influ-nRNA - Drug Profile

influenza [serotype A] vaccine - Drug Profile

influenza [strain A/H1N1] vaccine - Drug Profile

influenza [strain A/H1N1] vaccine - Drug Profile

influenza [strain A/H1N1] vaccine - Drug Profile

influenza [strain H1N1] (monovalent) vaccine - Drug Profile

influenza [strain H1N1] (mutivalent) vaccine - Drug Profile

influenza [strain H1N1] vaccine - Drug Profile

influenza [strain H1N1] vaccine - Drug Profile

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile

influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile

influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent, virus like particle) vaccine - Drug Profile

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile

influenza [strains A/H5N1 + A/H1N1] vaccine - Drug Profile

influenza vaccine - Drug Profile

influenza vaccine - Drug Profile

INO-3510 - Drug Profile

JNJ-872 - Drug Profile

LEAPS-H1N1-DC - Drug Profile

MBX-2329 - Drug Profile

MBX-2546 - Drug Profile

NEO-8877 - Drug Profile

NVINF-1 - Drug Profile

NVINF-2 - Drug Profile

pertussis [strain BPZE1] vaccine - Drug Profile

PNSIA-28 - Drug Profile

PNSIA-49 - Drug Profile

radavirsen - Drug Profile

Recombinant Protein to Target Sialic Acid Receptor for Influenza A Infections - Drug Profile

RNAi Oligonucleotides to Inhibit Matriptase for H1N1 Infection - Drug Profile

Small Molecules for RSV and Influenza A Infections - Drug Profile

Small Molecules to Agonize IRF-3 for Viral Infections - Drug Profile

Small Molecules to Block M2 Channel for Influenza Infections - Drug Profile

Small Molecules to Inhibit Influenza A Endonuclease for H1N1 Infections - Drug Profile

STP-702 - Drug Profile

Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile

TCN-032 - Drug Profile

TVX-002 - Drug Profile

VH-244 - Drug Profile

VIS-410 - Drug Profile

VNFC-045 - Drug Profile

VNFC-051 - Drug Profile

VXAA-1.1 - Drug Profile

Z-3G1 - Drug Profile

H1N1 Infection – Recent Pipeline Updates

H1N1 Infection - Dormant Projects

H1N1 Infection – Discontinued Products

H1N1 Infection – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for H1N1 Infection, H1 2016

Number of Products under Development for H1N1 Infection – Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Investigation by Universities/Institutes, H1 2016

H1N1 Infection – Pipeline by Adamas Pharmaceuticals, Inc., H1 2016

H1N1 Infection – Pipeline by Akshaya Bio Inc., H1 2016

H1N1 Infection – Pipeline by Altimmune, Inc., H1 2016

H1N1 Infection – Pipeline by Antigen Express, Inc., H1 2016

H1N1 Infection – Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016

H1N1 Infection – Pipeline by CEL-SCI Corporation, H1 2016

H1N1 Infection – Pipeline by Cilian AG, H1 2016

H1N1 Infection – Pipeline by CSL Limited, H1 2016

H1N1 Infection – Pipeline by EpiVax, Inc., H1 2016

H1N1 Infection – Pipeline by Etubics Corporation, H1 2016

H1N1 Infection – Pipeline by Gemmus Pharma Inc., H1 2016

H1N1 Infection – Pipeline by iBio, Inc., H1 2016

H1N1 Infection – Pipeline by ILiAD Biotechnologies, LLC, H1 2016

H1N1 Infection – Pipeline by Inovio Pharmaceuticals, Inc., H1 2016

H1N1 Infection – Pipeline by Johnson & Johnson, H1 2016

H1N1 Infection – Pipeline by Kineta, Inc., H1 2016

H1N1 Infection – Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016

H1N1 Infection – Pipeline by Medicago Inc., H1 2016

H1N1 Infection – Pipeline by MedImmune, LLC, H1 2016

H1N1 Infection – Pipeline by Microbiotix, Inc., H1 2016

H1N1 Infection – Pipeline by Mucosis B.V., H1 2016

H1N1 Infection – Pipeline by NanoViricides, Inc., H1 2016

H1N1 Infection – Pipeline by NewLink Genetics Corporation, H1 2016

H1N1 Infection – Pipeline by Novavax, Inc., H1 2016

H1N1 Infection – Pipeline by OPKO Health, Inc., H1 2016

H1N1 Infection – Pipeline by PeptiDream Inc., H1 2016

H1N1 Infection – Pipeline by Sarepta Therapeutics, Inc., H1 2016

H1N1 Infection – Pipeline by Sirnaomics, Inc., H1 2016

H1N1 Infection – Pipeline by Takeda Pharmaceutical Company Limited, H1 2016

H1N1 Infection – Pipeline by TechnoVax, Inc., H1 2016

H1N1 Infection – Pipeline by Theraclone Sciences, Inc., H1 2016

H1N1 Infection – Pipeline by Touchlight Genetics Limited, H1 2016

H1N1 Infection – Pipeline by United Therapeutics Corporation, H1 2016

H1N1 Infection – Pipeline by Vaxart, Inc., H1 2016

H1N1 Infection – Pipeline by Vironova AB, H1 2016

H1N1 Infection – Pipeline by Visterra, Inc., H1 2016

H1N1 Infection – Pipeline by Zydus Cadila Healthcare Limited, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

H1N1 Infection Therapeutics – Recent Pipeline Updates, H1 2016

H1N1 Infection – Dormant Projects, H1 2016

H1N1 Infection – Dormant Projects (Contd..1), H1 2016

H1N1 Infection – Dormant Projects (Contd..2), H1 2016

H1N1 Infection – Dormant Projects (Contd..3), H1 2016

H1N1 Infection – Discontinued Products, H1 2016

List of Figures

Number of Products under Development for H1N1 Infection, H1 2016

Number of Products under Development for H1N1 Infection – Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Adamas Pharmaceuticals, Inc.
Akshaya Bio Inc.
Altimmune, Inc.
Antigen Express, Inc.
Beijing Minhai Biotechnology Co., Ltd
CEL-SCI Corporation
Cilian AG
CSL Limited
EpiVax, Inc.
Etubics Corporation
Gemmus Pharma Inc.
iBio, Inc.
ILiAD Biotechnologies, LLC
Inovio Pharmaceuticals, Inc.
Johnson & Johnson
Kineta, Inc.
Kyowa Hakko Kirin Co., Ltd.
Medicago Inc.
MedImmune, LLC
Microbiotix, Inc.
Mucosis B.V.
NanoViricides, Inc.
NewLink Genetics Corporation
Novavax, Inc.
OPKO Health, Inc.
PeptiDream Inc.
Sarepta Therapeutics, Inc.
Sirnaomics, Inc.
Takeda Pharmaceutical Company Limited
TechnoVax, Inc.
Theraclone Sciences, Inc.
Touchlight Genetics Limited
United Therapeutics Corporation
Vaxart, Inc.
Vironova AB
Visterra, Inc.
Zydus Cadila Healthcare Limited
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll